|
US2021113659A1
|
|
Engineered therapeutic to enhance cytotoxic activity and phagocytosis in tumor associated macrophages
|
|
US2021113736A1
|
|
Oxygen-releasing biomaterials, articles and methods
|
|
WO2021076656A1
|
|
Rna editor-enhanced rna trans-splicing
|
|
WO2021076634A1
|
|
Aav production strategy using a cell line expressing an inducible rep gene
|
|
US2021109085A1
|
|
Methods for predicting er-mediated dna damage
|
|
WO2021072201A1
|
|
Raav-mediated in vivo delivery of suppressor trnas
|
|
WO2021071876A1
|
|
Photolytic compounds and triplet-triplet annihilation mediated photolysis
|
|
WO2021062202A1
|
|
Methods for depletion of deleterious mitochondrial genomes
|
|
WO2021062251A2
|
|
Targeting rlim to modulate body weight and obesity
|
|
WO2021061676A1
|
|
Multi-antigenic peptide mimics of gonococcal lipo-oligosaccharide (los) epitopes
|
|
US2021108200A1
|
|
BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY
|
|
US2021070786A1
|
|
Phosphonium-based zwitterionic monomers and polymers, and compositions and methods thereof
|
|
US2021072222A1
|
|
Compositions and methods for visualization of extracellular activity
|
|
WO2021046245A1
|
|
Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
|
|
US2021115442A1
|
|
O-methyl rich fully stabilized oligonucleotides
|
|
WO2021030672A1
|
|
Cell culture methods
|
|
WO2021030678A1
|
|
Targeting of the cytoskeleton as a therapeutic approach for neurodegenerative disease
|
|
WO2021030604A1
|
|
Urinary rna signatures in renal cell carcinoma (rcc)
|
|
WO2021030407A1
|
|
Diagnostic test for idiopathic normal pressure hydrocephalus
|
|
US2021071177A1
|
|
MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
|
